BRIEF—Phase III win for Zerviate in China

French ophthalmology company Nicox has announced positive results in a Chinese Phase III trial of Zerviate (cetirizine), run by its Chinese partner, Ocumension Therapeutics.

The product was found to be non-inferior to emedastine difumarate in the primary efficacy endpoint. The results are needed for Ocumension to begin regulatory interactions in China.

Zerviate is the first and only eye drop formulation of the antihistamine cetirizine, the active ingredient in Zyrtec, and is currently sold in the USA for ocular itching caused by allergic conjunctivitis.

The product is exclusively licensed to Ocumension Therapeutics for development and commercialization in the Chinese and the majority of the Southeast Asian markets.